ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)
BARCELONA, SPAIN and CAMBRIDGE MA.
• A new step in the collaboration to fight Alzheimer’s Disease
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Alzheimer’s Drug Discovery Foundation (ADDF) exercised warrants and lending rights over 175,071 ordinary shares of the Company, at an exercise price of EUR 3.43 per share (par value EUR 0.05 each) representing 0.6% of the capital.